| |
Case
Study: Using New Heart Failure Measure, Home Care Providers Reduce
Rehospitalizations
by Carolyn Humphrey, RN, MS, FAAN
If yours is a typical home care agency, patients with chronic conditions
such as heart failure have the strongest negative impact on your
rehospitalization rate. One would think that, with all the advanced
technology available to healthcare providers today, there would be a tool
able to detect an imminent heart exacerbation before the patient reaches the
stage where hospitalization is the only course of action.
Today, finally, there is such a technology. What’s more, it now comes in a
package small enough and light enough to be carried from home to home by a
nurse. This is its story. (Click on numbers in parentheses to read
author's footnotes.)
U.S. health realities create the need
As indicated in the American Heart Association’s 2008 statistics,(1)
the number of patients with Heart Failure (HF) promises to increase, which
means it will remain the #1 diagnosis seen in home care and providers will
continue to be pressed by all payers to find cost effective
clinical care that results in great outcomes for the least amount of money!
The reality is HF is a chronic disease that is difficult to keep under
control since its symptoms are linked to the heart’s ability to efficiently
pump fluid through the body. Without the correct combination of fluid
management, medications, and symptom monitoring, HF can rapidly get out of
control.
Caring for HF patients in home care means the nurse must first expertly
assess the patient’s co-morbidities, symptoms and the effects of medications
to develop a picture of each person’s unique disease path. Then, the nurse
must teach every patient how to identify their own path and how to care for
themselves.
This may not be so hard if you have the right tools. However, even though
health care has become high tech, we are still assessing whether HF patients
are collecting fluid, i.e. getting into problems, in the same, low-tech
ways, looking for:
-
weight gain
-
swelling of feet, ankles, abdomen or
legs
-
shortness of breath, frequent coughing,
or frequent coughs.
Unfortunately, by the time these symptoms
occur, fluid has already built up to a level where effective treatment
cannot be provided at home and away to the emergency room they go. Usually,
they need to be admitted and the home care agency is charged with a
rehospitalization on its Home Health Compare scores.
Stating the need
Wouldn't it be great if nurses had a way to
detect a patient’s HF problems before these traditional indicators even show
up?
OR
Wouldn't it be great if nurses could detect an imminent weight gain,
swelling or shortness of breath several days before it occurred and could
intervene early enough to avoid a trip to the hospital?
Addressing the need
We do. The method is to measure
Zo,(2)
shorthand for "Thoracic Base Impedance." This measure has been used by
physicians for over twenty years as a quick and easy way to determine
whether patients are experiencing fluid congestion or dehydration. They use
the ZOE® Fluid Status Monitor,(3)
made by Noninvasive Medical Technologies, which provides objective data to
guide early intervention of heart failure, end stage renal disease,
hypertension exacerbation as well as other critical events related to
hemodynamic status disruption.
Previously available only as part of a multi-function monitor, wheeled from
hospital room to room on a cart, the portable ZOE® Monitor now fits in a
small carrying case.
Research(4)
indicates that measuring Zo can predict congestion in heart failure cases as
early as two weeks prior to weight gain and other symptoms such as edema or
shortness of breath. Nurses then have more time to assess reasons behind the
changes and work with patients to change behaviors or improve medication
adherence. Often, they also consult with the patient’s physician, before
having to resort to disruptive and costly emergent care or
rehospitalization, to determine whether adjustments in the patient’s
treatment plan are indicated.
The ZOE® Monitor is FDA approved and intended for use by
qualified healthcare practitioners, under the direction of a physician, for
monitoring:
• Patients living with fluid management problems
• Patients taking diuretic medication
• Patients living with Heart Failure
• Patients living with End-Stage Renal Disease
• Patients recovering from a coronary artery disease related event
• Patients suffering from recurrent dehydration
Contraindications:
• Patients with allergies to electrode hydrogel
• Patients with skin sensitivities to electrode hydrogel
• Patients with skin breakdown in areas on the chest where ZOE®
Monitor electrode placement is required.
Measuring outcomes
One patient’s ZOE® experience
Mrs. S is a 71-year-old woman with a primary diagnosis of HF and secondary
diagnosis of insulin dependent diabetes. I interviewed Katherine, a home
care nurse, after she had been monitoring Mrs. S with the ZOE® Fluid
Status Monitor for six months.
Mrs. S’s medications are the expected ones for someone with her diagnoses:
insulin, a diuretic (lasix), potassium to counteract fluid loss from the
diuretic, and a beta blocker. She has a very attentive husband who, though
she playfully describes him as a man “any woman would die for,” needs a lot
of direction, education, and support when it comes to his caregiver duties.
Mrs. S was referred for in-home monitoring after having been hospitalized
several times for being “extremely wet” (fluid overload) and occasionally
for being “dry” (dehydrated). Her home care provider knew she needed more
ongoing monitoring than they could provide so they supplemented in-person
visits with services through their contract with Baseline Telehealth, Inc.,
the disease management company that employs Katherine.
Baseline provides telemonitoring in patients’ homes, including ZOE®
monitoring, and supplements nurses making in-person visits with office-based
critical care nurses, who provide additional patient support, education, and
intervention as needed.
Six months after Katherine began to see Mrs. S, she told me, "I am happy to
inform you that Mrs. S has not been hospitalized since being with us and
that the ZOE® Monitor is very helpful in letting me know when Mrs. S. needs
to be careful with her diet or drink more or less. The majority of the time
she showed no symptoms but her Zo readings indicated problems were present.
She would start to get compliant and her numbers would go up and then she
would start to get dehydrated but her weight did not change to reflect these
events.
"When I realized that the ZOE® Monitor was giving me advance warnings, I
started to rely on it all the time. Now, she gets a ZOE® Monitor reading
every other day and I review it. I have been able to call Mrs. S when she is
either too wet or dry and simply instruct her and her husband over the phone
to drink more or to restrict her fluid intake."
One home health agency's ZOE® experience
Trinity Home Health Services, with corporate offices in Novi, Michigan,
initiated a HF program a year ago called Hearts at Home. They
purchased ZOE® Monitors for each of their seven offices and integrated them
into their comprehensive disease management approach, which includes
patients conducting daily monitoring of their ZOE® readings and other data
and reporting them through the Pharos Tel-Assurance daily phone
survey program. Visits focus on patient education, covering disease
management, exercise and diet instructions for improved post-discharge self
care.
Suzanne Omtvedt, RN, CRNI, Infusion Clinical Specialist and Coordinator of
the Hearts at Home Program, "just loves" the ZOE® Monitor. "When I
observe a patient’s Zo readings fluctuate from baseline normal," she
explains, "I ask more questions about what the patient has eaten and whether
he has taken his medications correctly, searching for information to provide
clues to reasons behind the changes." When necessary, she contacts his
doctor.
"Our nurses have had several patients who have needed nothing more than
medication changes," Omtvedt continued. "A few days after their physicians
ordered the appropriate adjustments, their Zo readings returned to their
normal ranges. This meant they did not have to go through the old patterns,
waiting to develop breathing trouble and ankle swelling before we adjusted
their medicines."
|
Table 1 |
|
Trinity office A: ZOE monitored CHF
patients compared to
Medicare Home Health Compare state and national averages
|
|
Percent of
patients admitted to hospital (lower scores better): |
1st Quarter |
15% |
|
2nd Quarter |
14% |
|
|
3rd Quarter |
16% |
|
|
HHC
State Average |
27% |
|
|
HHC National
Average |
28% |
The data presented in Table 1 are outcome scores for the three quarters of
Trinity’s Home Care Compare data compared with state (Michigan) and national
averages from March 2008 posted scores. The office shown has the largest
number of HF patients, however, HF patient data from the other six offices
trends the same way.
|
Table 2 |
|
Trinity office A: ZOE monitored CHF
patients compared to
Medicare Home Health Compare state and national averages
|
|
Percent of
patients needing unplanned medical care (lower scores better): |
1st Quarter |
11% |
|
2nd Quarter |
13% |
|
|
3rd Quarter |
12% |
|
|
HHC
State Average |
21% |
|
|
HHC National
Average |
21% |
Although there are many factors that combine to affect overall agency scores
for these patients, Suzanne Omtvedt states, “The ability to monitor
patients’ Zo readings has had a major impact on our ability to call patients
to further assess what could be causing changes and then offer direct
teaching or contact a physician for medication orders. There is no question
that this early, direct communication with the patient has made a big
difference in our Home Care Compare outcomes and the cost savings we have
experienced in the program.”
Trinity has begun measuring the financial impact of the Hearts at Home
program (Table 3). Consideration of financial outcomes of such programs
should be reviewed keeping in mind possible additional costs imposed by the
program itself and potentially not calculated in published outcomes, as well
as the variability of costs over time. It is evident, however, from this
preliminary data that return on investment has been positive to the agency
while the program provides high quality care and outcomes.
|
Table 3 |
|
Trinity office A: Financial impact
of Hearts at Home program |
|
|
Average visits per episode |
Profit/Loss change
|
|
1st Quarter -
25 patients |
14.0 |
+$8,220.00 |
|
2nd Quarter -
14 patients |
16.4 |
+$4,153.00 |
|
3rd Quarter -
25 patients |
18.8 |
+$7,830.00 |
Adoption of the ZOE® Monitor is on the rise, both by home health agencies
and their
telehealth vendors. As case studies and aggregate data such as
presented in this article
become increasingly available, monitoring Zo is
perceived as a cutting edge technology
that decreases costs, improves
outcomes and increases patient satisfaction. Ongoing
work on compiling data
on case studies, programs and costs is a priority of the device's
manufacturer (http://www.nmtinc.org)
and distributor (www.omnimedicalsupply.com).
Carolyn Humphrey, RN, MS, FAAN, is a freelance writer and home care
consultant. She
is the president of her own consulting firm, CJ Humphrey
Associates. Carolyn is the
former editor of Home Healthcare Nurse
magazine. She lives in Louisville, KY and can
be reached at:
cjhumphrey@bellsouth.net.
This article first appeared in Home Care Automation
Report, April 16, 2008, editor Tim
Rowan. Reprinted by permission.
©2008 Stony Hill Publishing. For editorial comments
or to request a free
subscription, contact Stony Hill at
editor@homecareautomationreport.com. |